Neutrophil-to-lymphocyte ratio (NLR) is a significant prognostic indicator in myeloproliferative neoplasms, correlating with ...

Dr. Bachisio Ziccheddu is the first and presenting author. TP53 Alterations Confer Increased Risk of Leukemic Transformation ...

Myelofibrosis is a rare blood cancer part of the broader myeloproliferative neoplasms (MPNs) diseases. MPNs have an incidence rate of 2.05 new cases per 100,000 Canadians.v Currently there are between ...

Smoking then causes several distinct problems for people with P. vera; it worsens the production of red blood cells and damages the walls of the blood vessels, making heart attacks and strokes more ...

Prithviraj Bose, MD, discusses the most critical adverse effects seen with each of the 4 approved JAK inhibitors for the treatment of myeloproliferative neoplasms.

Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III Session Date: Monday, December 9, 2024 Presentation Time: 6:00 PM - 8:00 PM PST Location: San Diego Convention Center, Halls G-H ...

Taiho Oncology Inc. announced today presentations at the 66th American Society of Hematology (ASH) Annual Meeting, to be held ...

The first presentation will describe long term follow-up from patients in Part 1 of the ongoing APEX trial. APEX is a global, open-label, multi-center, two-part Phase 2 clinical trial evaluating the ...

"Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase ...

A phase 1 study of tapotoclax in high-risk myelodysplastic syndromes demonstrated the agent was tolerable but showed limited efficacy.

Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced the dosing ...